Program

Program Wednesday, May 23, 2018

7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIUM
7:15 AM - 8:15 AM
Room: 309 (Level 300)
BRIDGING THE GAP BETWEEN RETROSPECTIVE DATA AND REGISTRIES: WHERE DO WE GO FROM HERE?

(Sponsored by Ipsos Healthcare)

8:00 AM - 3:00 PM
SPEAKER READY ROOM HOURS (Room 311 (Level 300))
Room: 311 (Level 300)
8:00 AM - 4:00 PM
REGISTRATION HELP DESK HOURS (Charles Street Lobby, Baltimore Convention Center)
Room: Charles Street Lobby (Level 100)
8:00 AM - 4:00 PM
MULTI-FAITH PRAYER ROOM (Ballroom VIP East Suite (Level 400))
Room: Ballroom VIP East Suite (Level 400)
8:00 AM - 4:00 PM
NURSING MOTHER'S ROOM (Ballroom VIP Suite West (Level 400))
Room: Ballroom VIP Suite West (Level 400)
8:30 AM - 9:30 AM
BREAKOUT SESSION

8:30 AM - 9:30 AM
Room: Ballroom I (Level 400)

IP18: WHEN RESEARCH QUESTIONS COLLIDE: HOW MUCH IS THE UNITED STATES ACTUALLY SPENDING ON DRUGS?

Moderator:

Michael Kleinrock, MA, Research Director, IQVIA Institute for Human Data Science, Plymouth Meeting, PA, USA

Panelists:

Sean Keehan, MA, Economist, Office of the Actuary, Centers for Medicare and Medicaid Services, Baltimore, MD, USA

Cynthia Cox, MPH, Director, Program for the Study of Health Reform and Private Insurance, Kaiser Family Foundation, Washington, DC, USA

Sara Sadownik, MSc, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission, Boston, MA, USA


8:30 AM - 9:30 AM
Room: Ballroom II (Level 400)

IP19: VALUE ASSESSMENT FRAMEWORKS IN AN ERA OF PERSONALIZED MEDICINE: SHARED OBJECTIVES OR IRRECONCILABLE DIFFERENCES?

Moderator:

Kristen Migliaccio-Walle, BS, Director, Global Health Economics & Outcomes Research, Xcenda, LLC, Palm Harbor, FL, USA

Panelists:

Daniel A Ollendorf, PhD, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA

Robert W Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA

Sara Traigle van Geertruyden, JD, Executive Director, Partnership to Improve Patient Care, Washington, DC, USA


8:30 AM - 9:30 AM
Room: Ballroom III (Level 400)
W17: DO CUTTING-EDGE ONE-TIME TREATMENTS NEED EQUALLY INNOVATIVE-, OUTCOMES-, OR ANNUITY-BASED PAYMENT MODELS?
Discussion Leaders:

Mark Chalmers, PhD, Principal & EU Lead, CBPartners, London, UK

Andrew Gould, MS, Principal, CBPartners, New York, NY, USA

Maximilian Hunt, BSc, Principal, CBPartners, New York, NY, USA

Omar Ali, BSc, DipClinPharm, MRPharmS, ACPP, Pharmacy Director, QIPP Adviser Commissioning Payer Network & former ERG Cost Impact Modelling, NICE, London, UK


8:30 AM - 9:30 AM
Room: Ballroom IV (Level 400)
W18: OPEN SOURCE SOFTWARE FOR BUILDING HEALTH ECONOMIC MODELS
Discussion Leaders:

Joseph F Levy, BS, Postdoctoral Fellow, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

Fernando Alarid-Escudero, PhD, Post-Doctoral Associate, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, USA

Erik J Dasbach, PhD, Executive Director, Outcomes Research, Merck & Co. Inc., Kenilworth, NJ, USA


8:30 AM - 9:30 AM
Room: 309 (Level 300)
P13: CONCEPTUAL PAPERS
Moderator: Karen Rascati, RPh, PhD
Professor, The University of Texas College of Pharmacy, Austin, TX, USA

CP1

8:30 AM - 8:45 AM

AN ANALYTICAL FRAMEWORK FOR ECONOMIC EVALUATION OF INTERVENTIONS WITH EFFECTS ON MULTIPLE OUTCOMES, COSTS FALLING ON DIFFERENT BUDGETS, AND INVOLVING MORE THAN ONE DECISION MAKER

Griffin S1, Walker S2, Sculpher M1, Asaria M2
1University of York, York, UK, 2University of York, Heslington, York, UK

CP2

8:45 AM - 9:00 AM

GRAPHICAL PROBABILISTIC MODELS FOR RISK PREDICTION AND DECISION MAKING USING REAL-WORLD DATA: A DEVELOPING TOOL FOR THE ERA OF PRECISION MEDICINE

Arora P1, Boyne DJ2, Druzdzel MJ3
1Lighthouse Outcomes, Toronto, ON, Canada, 2University of Calgary, Calgary, ON, Canada, 3University of Pittsburgh, Pittsburgh, PA, USA

CP3

9:00 AM - 9:15 AM

ASSESSMENT-TIME BIAS: STATISTICAL APPROACHES TO ADJUSTING FOR BETWEEN-TRIAL DIFFERENCES IN THE SCHEDULE OF ASSESSMENT FOR DISEASE PROGRESSION IN IMMUNO-ONCOLOGY TRIALS

Kapetanakis V1, Schlichting M2, Stevens JW3, Prawitz T1, Kearney M4, Phatak H5, Benedict A6, Bharmal M4
1Evidera, London, UK, 2Merck KGaA, Darmstadt, Germany, 3Reader in Decision Science, University of Sheffield, Sheffield, UK, 4Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany, 5EMD Serono, Rockland, MA, USA, 6Evidera, Budapest, Hungary

CP4

9:15 AM - 9:30 AM

BUDGET IMPACT ANALYSIS WITH SIMULTANEOUS MULTIPLE MARKET ENTRANTS: STATIC VERSUS DYNAMIC BASELINE MARKET SHARES

O'Day K1, Meyer K2
1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda, Palm Harbor, FL, USA

8:30 AM - 9:30 AM
Room: 310 (Level 300)
P14: HEALTHCARE RESOURCE USE AND EXPENDITURE STUDIES
Moderator: Brian Rittenhouse
Associate Professor, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, USA

HE1

8:30 AM - 8:45 AM

EFFECT OF A PROVIDER-FOCUSED ASTHMA CARE QUALITY IMPROVEMENT PROGRAM ON PATIENT-LEVEL ASTHMA-RELATED HEALTH CARE COSTS

Rojanasarot S, Carlson AM, St. Peter WL, Schommer JC
College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

HE2

8:45 AM - 9:00 AM

HEALTH CARE COSTS IN DIABETES: THE ROLE OF COMORBIDITY TYPE

Lin P1, Pope E1, Zhou FL2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, 2Sanofi, Bridgewater, NJ, USA

HE3

9:00 AM - 9:15 AM

A TALE OF TWO UNIVERSAL HEALTH INSURANCE SCHEMES IN ONE COUNTRY: HORIZONTAL INEQUALITY OF GOVERNMENT MEDICAL AND PHARMACEUTICAL BENEFITS FOR AUSTRALIAN CHILDREN

Huang L, Clarke P, Dalziel K
The University of Melbourne, Melbourne, Australia

HE4

9:15 AM - 9:30 AM

REAL-WORLD ANALYSIS OF TREATMENT PATTERNS AND LONG-TERM EFFECTIVENESS AMONG PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS OF LUNG ORIGIN (LUNG NET): A MULTICENTER STUDY

Dasari A1, Bergsland EK2, Benson AB3, Cai B4, Huynh L5, Totev T5, Shea J5, Duh MS5, Neary MP4, Kulke MH6
1University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, 3Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Analysis Group, Inc., Boston, MA, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA
8:30 AM - 1:30 PM
RESEARCH POSTER PRESENTATIONS - SESSION V
8:30 AM - 2:00 PM
EXHIBIT/POSTER HALL HOURS (Hall B,C,D, Baltimore Convention Center)
Room: Hall B,C,D (Level 100)
9:30 AM - 10:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
Room: Hall B,C,D (Level 100)
10:00 AM - 11:45 AM
WELCOME & THIRD PLENARY SESSION
Room: Hall A (Level 100)
WELCOME FROM ISPOR PRESIDENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Hall A (Level 100)
ISPOR SERVICE AWARDS
Presented by: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Hall A (Level 100)
ISPOR STUDENT AWARDS
Presented by: Zeba M. Khan, MS, RPh, PhD
ISPOR Student Network Advisor and Vice President, Celgene Corporation, Summit, NJ, USA
Room: Hall A (Level 100)
PHRMA FOUNDATION AWARDS
Presented by: Nancy S. Santanello, MD, MS, FISPE
PhRMA Health Outcomes Advisory Committee, Independent Research Consultant, New Hope, PA, USA
Room: Hall A (Level 100)
ISPOR 2019 MEETING ANNOUNCEMENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Hall A (Level 100)
THIRD PLENARY SESSION: EXAMINING THE ROLE OF PATIENT PREFERENCES TO INFORM REGULATORY DECISIONS
The US Food and Drug Administration (FDA) user fee agreements (MDUFA IV and PDUFA VI) require the FDA to develop systematic approaches to develop fit-for-purpose tools to collect meaningful patient input that can be incorporated into regulatory review. The Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH) have taken different but complementary approaches to incorporate views of patients. CDRH has worked to understand quantitative preference elicitation methods to ascertain patients’ views about benefits and risks of medical products. CDER has focused on the qualitative preference elicitation methods. Preference researchers argue that when carefully conducted, stated-preference studies generate valid scientific evidence on patients’ views about relative desirability of harms, risks, benefits, and other features related to treatment alternatives. However, critics of preference research point out that humans often rely on decision heuristics, have poor numeracy, and fail tests of internal consistency. The panel will debate the strengths and limitations of stated-preference research and the extent to which patients’ views on benefit-risk tradeoffs for medical therapies can be relied upon to inform regulatory decisions.
Moderator: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Speaker: Bennett Levitan, MD, PhD
Senior Director, Benefit-risk Assessment, Department of Epidemiology, Janssen Research & Development, Titusville, NJ, USA
Speaker: Matt Reaney, FRSPH, MSc
Global Head of Clinical Outcomes, Sanofi, Guildford, Surrey, UK
Speaker: Jeff Shuren, MD, JD
Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA
11:45 AM - 1:45 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V
Room: Hall B,C,D (Level 100)
12:30 PM - 1:30 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION V
Room: Hall B,C,D (Level 100)
1:45 PM - 2:45 PM
BREAKOUT SESSION

1:45 PM - 2:45 PM
Room: Ballroom I (Level 400)

IP20: THE PATIENT PERSPECTIVE AND VALUE ASSESSMENT: EASY TO IDENTIFY THE NEED, HARD TO AGREE ON THE SOLUTION

Moderator:

Mike Ciarametaro, MBA, Vice President, National Pharmaceutical Council, Washington, DC, USA

Panelists:

Ilene L. Hollin, PhD, MPH, Health Policy Fellow, National Pharmaceutical Council and University of Southern California Schaeffer Center for Health Policy and Economics, Washington, DC, USA

David Wamble, MS, MBA, Director, Health Economics, RTI Health Solutions, Durham, NC, USA

Josh Seidman, PhD, MHS, Senior Vice President, Avalere, Washington, DC, USA


1:45 PM - 2:45 PM
Room: Ballroom II (Level 400)

IP21: IS ARTIFICIAL INTELLIGENCE THE NEXT BIG THING IN HEALTHCARE DECISION MAKING?

Moderator:

Santiago Ernesto Herran, MD, Market Access Head, Bayer Andina, Bogota, Colombia

Panelists:

Rafael Alfonso Cristancho, MD, MSc, PhD, Senior Director, Value Evidence Outcomes, R&D, GlaxoSmithKline, Collegeville, PA, USA

Juan-David Rueda, MD, MS, Doctoral Candidate, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

Carrie Savage Bennette, PhD, MPH, Senior Methodologist, Flatiron, NY, NY, USA


1:45 PM - 2:45 PM
Room: 310 (Level 300)
W19: MEDICAL DEVICE REAL-WORLD EVIDENCE FOR BEGINNERS: A PRIMER
Discussion Leaders:

Stephen S Johnston, MA, Director, Johnson & Johnson, Inc., New Brunswick, NJ, USA

Joshua Gagne, PharmD, ScD, Associate Professor of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics; Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Frank R. Ernst, PharmD, MS, Executive Director, Real-World Evidence, CTI Clinical Trial and Consulting Services, Covington, KY, USA

Abhishek S Chitnis, MPharm, PhD, Associate Director, Epidemiology, Medical Devices, Real World Analytics and Research, Johnson & Johnson, New Brunswick, NJ, USA


1:45 PM - 2:45 PM
Room: Ballroom IV (Level 400)
W20: FIXING THE TOWER OF BABEL: ESTABLISHING A COMMON METRIC FOR PATIENT-REPORTED OUTCOME MEASURES
Discussion Leaders:

Jakob B. Bjorner, MD, PhD, CSO, Optum Patient Insights, Johnston, RI, USA

Benjamin D. Schalet, PhD, Research Assistant Professor of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Felix Fischer, PhD, Researcher, Department for Psychosomatic Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany

Ian Kudel, PhD, Senior Scientist, Optum Patient Insights, Johnston, RI, USA


1:45 PM - 2:45 PM
Room: 309 (Level 300)
W21: PRINCIPLES OF EFFECTIVE MACHINE LEARNING APPLICATIONS IN REAL WORLD EVIDENCE
Discussion Leaders:

Andrew Cox, PhD, Research Scientist, Data Analytics, Evidera, London, UK

Sreeram Ramagopalan, Ph.D, Director, Center for Observational Research and Data Sciences (CORDS), Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK

Gorana Capkun-Niggli, PhD, Head of HEOR Innovation, Novartis Pharma AG, Basel, Switzerland

David J. Vanness, PhD, Associate Professor, Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA


1:45 PM - 2:45 PM
Room: Ballroom III (Level 400)
P15: UTILITY AND PATIENT PREFERENCE STUDIES
Moderator: John E. Brazier, PhD, FMedSci
Professor of Health Economics and Dean of ScHARR, University of Sheffield, Sheffield, UK

PP1

1:45 PM - 2:00 PM

PATIENT PREFERENCES FOR HEALTH STATES FOLLOWING ALTERNATIVE MANAGEMENT OPTIONS FOR DUCTAL CARCINOMA IN SITU

Campbell BM1, Yang J2, Gonzalez JM2, Reed SD2, Havrilesky L3, Johnson FR2, Hwang ES3
1Duke University School of Medicine, Durham, NC, USA, 2Duke Clinical Research Institute, Durham, NC, USA, 3Duke Cancer Insitute, Durham, NC, USA

PP2

2:00 PM - 2:15 PM

CHOICE DEFINES QALYS: A US VALUATION OF THE EQ-5D-5L

Craig BM1, Rand K2
1University of South Florida, and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA, 2University of Oslo, Oslo, Norway

PP3

2:15 PM - 2:30 PM

ESTIMATING THE HEALTH STATE UTILITY OF PATIENTS WITH HER2– GBRCA+ METASTATIC BREAST CANCER TREATED WITH OLAPARIB OR CHEMOTHERAPY VIA A MAPPING ANALYSIS OF EORTC QLQ-C30 DATA COLLECTED IN THE OLYMPIAD CLINICAL TRIAL

Robson M1, Hettle R2, Degboe A3, Saunders O4, Cain T4, Kilvert H4, Johnson H4
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2AstraZeneca, Cambridge, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4Bresmed Ltd, Sheffield, UK

PP4

2:30 PM - 2:45 PM

CONSUMER PREFERENCES FOR PRECISION MEDICINE TECHNOLOGIES: EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT

Regier DA1, Veenstra DL2, Basu A3, Saha J2, Carlson JJ3
1BC Cancer/University of British Columbia, Vancouver, BC, Canada, 2Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA
2:45 PM - 3:00 PM
BREAK
Room: Hall B,C,D (Level 100)
3:00 PM - 4:00 PM
BREAKOUT SESSION

3:00 PM - 4:00 PM
Room: Ballroom I (Level 400)

IP22: CHALLENGES AND OPPORTUNITIES IN THE USE OF REAL-WORLD EVIDENCE FOR REGULATORY DECISION MAKING FOR IN VITRO DIAGNOSTICS

Moderator:

Tyler J. O'Neill, DVM, MSc, PhD, Scientist, Diagnostics Information Solutions, Roche Diagnostics, Pleasanton, CA, USA

Panelists:

Michael S. Waters, PhD, SHIELD Team Lead; CDRH RWE Tactical Team – Diagnostics, Office of in vitro Diagnostics and Radiologic Health (OIR), Food and Drug Administration (FDA), Silver Spring, MD, USA

Brad Spring, BS, Vice President, Regulatory Affairs, BD Life Sciences, Sparks, MD, USA

Asif Jan, PhD, Lead, Diagnostics Information Solutions, Roche Diagnostics, Pleasanton, CA, USA


3:00 PM - 4:00 PM
Room: Ballroom II (Level 400)

IP23: ESTIMATING SAMPLE SIZE FOR QUALITATIVE RESEARCH IN CLINICAL OUTCOME ASSESSMENT RESEARCH: ONE SIZE DOES NOT FIT ALL!

Moderator:

Helen Kitchen, MSc, Senior Consultant, Clinical Outcomes Assessment, DRG Abacus, Manchester, UK

Panelists:

Kathryn Lasch, PhD, Executive Director, Patient Reported Outcomes, Pharmerit International, Newton, MA, USA

Helen Doll, PhD, Strategic Lead, Quantitative Science, Clinical Outcomes Solutions, Folkestone, UK

Katy Benjamin, PhD, Director, HEOR - Patient Reported Outcomes, Abbvie Inc, Chicago, IL, USA


3:00 PM - 4:00 PM
Room: Ballroom III (Level 400)
W22: THE MEDIUM IS THE MESSAGE: USING INTERACTIVE GRAPHICS TO EFFECTIVELY COMMUNICATE HEALTH ECONOMICS AND OUTCOMES RESEARCH FINDINGS
Discussion Leaders:

Shelagh M Szabo, MSc, Principal and Scientific Director, Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada

Ross Tsuyuki, MSc PharmD, Professor, University of Alberta, Edmonton, AB, Canada

Andrew Lloyd, DPhil, Director, Acaster Lloyd Consulting Ltd., London, UK

Bonnie M Donato, PhD, Senior Director, Global Health Outcomes, Alexion Pharmaceuticals, Inc, New Haven, CT, USA


3:00 PM - 4:00 PM
Room: Ballroom IV (Level 400)
W23: ESTIMATING THE COST OF ADVERSE EVENTS IN ECONOMIC MODELS: A DISCUSSION OF REAL-WORLD DATA VERSUS TREATMENT GUIDELINES BASED METHODOLOGIES
Discussion Leaders:

William Wong, PharmD, MS, Sr. Health Economist, US Medical Affairs, Genentech, Inc., South San Francisco, CA, USA

Martin Cloutier, MSc, Manager, Analysis Group, Inc., Montreal, QC, Canada

Josh J. Carlson, MPH, PhD, Associate Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA


3:00 PM - 4:00 PM
Room: 309 (Level 300)
P16: INFECTIOUS DISEASE AND RESPIRATORY STUDIES
Moderator: Fadia T. Shaya, PhD, MPH
Professor and Vice-Chair for Academic Affairs PHSR, University of Maryland School of Pharmacy, Baltimore, MD, USA

IN1

3:00 PM - 3:15 PM

USING ELECTRONIC HEALTH RECORDS TO EXAMINE HPV VACCINE INITIATION AND COMPLETION RATES

Yu J, Buikema AR, Togun A
Optum, Eden Prairie, MN, USA

IN2

3:15 PM - 3:30 PM

LONG-TERM HEALTH BENEFIT OF IBALIZUMAB IN THE TREATMENT OF ADULTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION

Brogan AJ1, Talbird SE2, Davis AE2, La EM2, Miao Z3, Lewis S4
1RTI Health Solutions, Didsbury, Manchester, NC, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Theratechnologies Inc., Montréal, QC, Canada, 4TaiMed Biologics, Irvine, CA, USA

IN3

3:30 PM - 3:45 PM

INCIDENCE OF HEPATOCELLULAR CARCINOMA AND EXTRAHEPATIC CANCERS AMONG HCV-INFECTED PATIENTS IN THE ERA OF DIRECT-ACTING ANTIVIRALS

Wang W1, Lo Re III V2, Xiao H1, Brown J1, Yi G1, Park H1
1University of Florida, Gainesville, FL, USA, 2University of Pennsylvania, Philadelphia, PA, USA

IN4

3:45 PM - 4:00 PM

ESTIMATING THE CURRENT COST OF ENDOSCOPIC SINUS SURGERY IN THE US – A CLAIMS-BASED APPROACH

Velez FF1, Sacks H1, Messina J1, Kozma CM2, Malone D3, Mahmoud R1
1OptiNose US, Inc., Yardley, PA, USA, 2CK Consulting Associates, LLC, Saint Helena Island, SC, USA, 3University of Arizona, Tucson, AZ, USA

3:00 PM - 4:00 PM
Room: 310 (Level 300)
P17: NEUROLOGICAL CONDITIONS STUDIES
Moderator: Michael T. Halpern, MD, PhD, MPH
Associate Professor, Temple University College of Public Health, Philadelphia, PA, USA

ND1

3:00 PM - 3:15 PM

USE OF DISEASE MODIFYING AGENTS IN PATIENTS WITH MULTIPLE SCLEROSIS: ANALYSIS OF TEN YEARS OF NATIONAL DATA

Earla JR1, Paranjpe R1, Kachru N2, Aparasu RR1
1University of Houston, Houston, TX, USA, 2Gilead Sciences Inc., Foster City, CA, USA

ND2

3:15 PM - 3:30 PM

HOW PRESCRIPTION DRUG COST FOR DISEASE MODIFYING THERAPY (DMT) IMPACTS OVERALL HEALTH CARE SPENDING AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS

Kim Y1, Krause TM1, Freeman L2
1The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA, 2The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA

ND3

3:30 PM - 3:45 PM

PRODUCTIVITY LOSSES AMONG PATIENTS WITH MIGRAINE: AN ANALYSIS OF ERENUMAB CLINICAL TRIAL DATA

Porter JK1, Di Tanna GL1, Lipton RB2, Sapra S3, Villa G1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Albert Einstein College of Medicine, Bronx, NY, USA, 3Amgen Inc, Thousand Oaks, CA, USA

ND4

3:45 PM - 4:00 PM

COST-UTILITY ANALYSIS COMPARING ABOBOTULINUMTOXINA WITH ONABOTULINUMTOXINA FOR THE TREATMENT OF PEDIATRIC LOWER LIMB SPASTICITY

Johnston KM1, Hansen RN2, Cheung A1, Liovas A3, Armstrong A3, Danchenko N4, Bains S5, Dinet J4, Sullivan SD2
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2University of Washington, Seattle, WA, USA, 3Ipsen Biopharmaceuticals Canada, Mississauga, ON, Canada, 4Ipsen Global, Boulogne-Billancourt, France, 5Ipsen US, Basking Ridge, NJ, USA
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.